Vascular Biogenics Ltd

Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company, concentrating on creating predictive, personalized treatments for individuals battling cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), the company virtually tests potential cancer therapies to forecast an individual patient's likely response to a specific drug. The primary goal of the PPMP is to identify and qualify patients who are expected to respond favorably before they even begin treatment, thereby significantly accelerating the clinical development process for these specific patient groups. Notable Labs' current development pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor designed to treat acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes. Additionally, it features Fosciclopirox, a prodrug of ciclopirox, also aimed at acute myeloid leukemia. The company's headquarters are located in Foster City, California.